Anyone know of any company that had less than 12 months of cash on hand that got a good deal for a ph ii compound…?
Reata’s $450M deal with ABT for Bardoxolone (#msg-54747777) may qualify, although Reata’s pre-deal financial status isn’t precisely known because the company is private.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.